🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Circulating Immunes Cells, Cytokines and Brain Radiotherapy

RecruitingNAAges 18 Years - anyAllCentre Francois Baclesse
NCT05082961 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Patients with malignant tumours of the cephalic pole have a poor prognosis, despite a wide range of treatments. prognosis despite a large therapeutic arsenal. Among this arsenal, radiotherapy (RT) is one of the standard treatments for these tumours. However, this treatment can cause damage to the surrounding healthy tissue, has limited efficacy in hypoxic However, this treatment can cause damage to the surrounding healthy tissue, has limited efficacy in hypoxic tissue and can promote pro-tumour inflammation. In these circumstances, hadrontherapy, which uses charged heavy particles, such as protons or carbon ions, is the preferred treatment. protons or carbon ions, seems more appropriate for the treatment of these tumours. However, although inflammation plays a major role in tumour development and tumour development and therapeutic response, few studies have evaluated the immune response

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients \> 18 years * Head and neck cancer: (upper aerodigestive tract, cavum, facial sinus, skull base, brain) operated * Surgery for complete tumour resection or with microscopic residue R1 * All possible histologies: squamous cell carcinoma, undifferentiated carcinoma of the nasopharyngeal type (UCNT), adenocarcinoma, adenoid cystic carcinoma, chordoma, chondrosarcoma,meningioma other tumours * Patients undergoing exclusive postoperative radiotherapy with a minimum total dose of 54 Gy of X-ray photon radiation or equivalent proton radiation. * Patient affiliated to a social security scheme * Signature of the informed consent before any specific procedure related to the study Exclusion Criteria: * Macroscopic postoperative tumour residue R2 * Previous cancer within 5 years (except treated basal cell skin carcinoma and treated cervical cancer). * Previous radiotherapy (except brachytherapy of the cervix or prostate) * Chemotherapy or other systemic oncological treatment (cetuximab) concomitant with radiotherapy * Long-term immunosuppressive or corticosteroid therapy * Patient deprived of liberty or under guardianship, protected adult * Patient unable to undergo trial monitoring for geographical, social or psychopathological reasons * Pregnant or breastfeeding woman * Emergency situations
💊

What it tests

  • Collection of blood samples
📍

Where

1 site
Centre François Baclesse
Caen, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy